Objective: To evaluate the efficacy and safety of Buyanghuanwu (BYHW) decoction for the treatment of ischemic stroke convalescence. Methods: CNKI, Wanfang knowledge service platform, VIP journal database, Chinese biom...Objective: To evaluate the efficacy and safety of Buyanghuanwu (BYHW) decoction for the treatment of ischemic stroke convalescence. Methods: CNKI, Wanfang knowledge service platform, VIP journal database, Chinese biomedical literature database (CBM), Pubmed, the Cochrane Library, Science Citation Index (SCI) and Elsevier SD databases were searched from the origin time to May 2018. Cochrane recommended bias risk assessment method was used to evaluate the bias risk. Review Manager 5.3 was used to perform meta-analysis. Results: A total of 12 studies with a 1246 cases were included in the study. The results of the analysis showed that the efficacy of BYHW decoction combined with western medicine treatment was better than that of control group (OR = 2.88, 95% CI (2.10,3.95), P < 0.001)]. The neurological deficit score in the treatment group was lower than that in the control group, and the difference was statistically significant [MD =-2.84, 95% CI (-3.22,-2.45), P < 0.001]. The scores of daily living ability in the treatment group were higher than those in the control group, and the difference was statistically significant [MD = 8.89, 95% CI (7.61, 10.16), P <0.00001]. In the safety aspect, the results of the study are different, and there was a lack of quantitative indicators to evaluate the objectivity of adverse reactions. Conclusion: BYHW decoction combined with the Western medicine is an effective treatment for the recovery period of cerebral infarction, which can significantly improve the clinical efficacy, improve patients' neurological symptoms and their quality of life.展开更多
文摘Objective: To evaluate the efficacy and safety of Buyanghuanwu (BYHW) decoction for the treatment of ischemic stroke convalescence. Methods: CNKI, Wanfang knowledge service platform, VIP journal database, Chinese biomedical literature database (CBM), Pubmed, the Cochrane Library, Science Citation Index (SCI) and Elsevier SD databases were searched from the origin time to May 2018. Cochrane recommended bias risk assessment method was used to evaluate the bias risk. Review Manager 5.3 was used to perform meta-analysis. Results: A total of 12 studies with a 1246 cases were included in the study. The results of the analysis showed that the efficacy of BYHW decoction combined with western medicine treatment was better than that of control group (OR = 2.88, 95% CI (2.10,3.95), P < 0.001)]. The neurological deficit score in the treatment group was lower than that in the control group, and the difference was statistically significant [MD =-2.84, 95% CI (-3.22,-2.45), P < 0.001]. The scores of daily living ability in the treatment group were higher than those in the control group, and the difference was statistically significant [MD = 8.89, 95% CI (7.61, 10.16), P <0.00001]. In the safety aspect, the results of the study are different, and there was a lack of quantitative indicators to evaluate the objectivity of adverse reactions. Conclusion: BYHW decoction combined with the Western medicine is an effective treatment for the recovery period of cerebral infarction, which can significantly improve the clinical efficacy, improve patients' neurological symptoms and their quality of life.
